Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients

Completed · Not applicable

Conditions studied: Atelectasis

In brief

Despite the lack of trials proving the efficacy of DNase in non cystic fibrosis patients, it is currently heavily used in this population. In fact, per evidence of barcode scanning via Meditech computer system at OU Medical Center 93% of the DNase prescribed in 2005 was for non Cystic fibrosis patients with an estimated yearly cost of $341,968.15.In vitro studies showed that the effect of Dnase was minimal on sputum viscosity when compared to Hypertonic saline . Furthermore recent studies on hypertonic saline in cystic fibrosis patients showed that it is an inexpensive and safe therapy when preceded by a bronchodilator in patients with cystic fibrosis. We hereby propose a prospective randomized trial to compare the efficacy of hypertonic saline, DNase, vs. normal saline in the treatment of atelectasis in non cystic fibrosis, mechanically ventilated patient.

Key facts

Study ID: NCT00671723
Run by: University of Oklahoma
People needed: 33
Starts: 2006-10-01
Expected to finish: 2008-07-01
Last updated by the study team: 2017-07-02

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patient on invasive mechanical ventilation
New Onset (<48 hours) lobar or multilobar lung atelectasis based on CXR

You may not qualify if…

Asthma
Severe COPD (FEV1<30%)
Pneumothorax or massive pleural effusion, thought to be causing the atelectasis
Lobar atelectasis secondary to compressive tumor.
Severe hypoxemia (PaO2/FiO2 < 75)
Hemodynamic Instability
Cystic fibrosis patients
Allergy to DNase
Patients on Acetylcysteine
Pregnant women

Where it is running

Presbyterian Hospital — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.